Characteristics | ALL (n = 332) | Monogenic Disease (n = 100) | Genetic-Testing Negative(n = 232) |
---|---|---|---|
Gender(male/female) | 219/113 | 58/42 | 161/71 |
Age at onset(months), median (IQR) | 69.9 ± 50.4 | 68.2 ± 53.6 | 70.6 ± 49.1 |
Clinical classification | Â | Â | Â |
 Without glomerular hematuria, renal insufficiency and hypocomplementemia, n(%) | 143/332(43.1) | 30/100(30.0) | 113/232(48.7) |
 With glomerular hematuria or/and renal insufficiency or/and hypocomplementemia, n(%) | 189/332(56.9) | 70/100(70.0) | 119/232(51.3) |
Histopathological findings | Â | Â | Â |
 MCD, n(%) | 85/168(50.6) | 13/42(30.9) | 72/126(57.1) |
 FSGS, n(%) | 55/168(32.7) | 18/42(42.9) | 37/126(29.4) |
 MSPGN, n(%) | 7/168(4.2) | 4/42(9.5) | 3/126(2.4) |
 MPGN, n(%) | 5/168(3.0) | 1/42(2.4) | 4/126(3.2) |
 Others1, n(%) | 16/168(9.5) | 6/42(14.3) | 10/126 (7.9) |
 None, n(%) | 164/332(49.4) | 58/100(58.0) | 106/232(45.7) |
Length of follow-up(months), median (IQR) | 25.4(10.0-47.6) | 23.5(3.1–44.1) | 25.8(11.6–48.8) |
Renal survival rate, n(%) | 308/332(92.8) | 80/100(80.0) | 228/232(98.3) |
Treatment | Â | Â | Â |
Steroid + TAC, n(%) | 214/332(64.4) | 52/100(52.0) | 162/232(69.8) |
 Complete, n(%) | 108/214(50.5) | 15/52(28.8) | 93/162(57.4) |
 Particle, n(%) | 52/214(24.3) | 9/52(17.3) | 43/162(26.5) |
 Resistance, n(%) | 50/214(23.3) | 25/52(48.1) | 25/162(15.4) |
 Unknow, n(%) | 4/214(1.9) | 3/52(5.8) | 1/162(0.6) |
Steroid + MMF/CTX, n(%) | 53/332(16.0) | 13/100(13.0) | 40/232(17.2) |
 Complete, n(%) | 12/53(22.6) | 2/13(15.4) | 10/40 [25] |
 Particle, n(%) | 13/53(24.5) | 1/13(7.7) | 12/40 [30] |
 Resistance, n(%) | 24/53(45.3) | 10/13(76.9) | 14/40 [35] |
 Unknow, n(%) | 4/53(7.6) | 0/13(0) | 4/40 [10] |
Others2, n(%) | 65/332(19.6) | 35/100(35.0) | 30/232(12.9) |
 Complete, n(%) | 2/65(3.1) | 0/35(0) | 2/30(6.7) |
 Particle, n(%) | 1/65(1.5) | 0/35(0) | 1/30(3.3) |
 Resistance, n(%) | 49/65(75.4) | 33/35(94.3) | 16/30(53.3) |
 Unknow, n(%) | 13/65 [20] | 2/35(5.7) | 11/30(36.7) |